These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 23816428)

  • 1. The social impact of Parkinson's disease in Spain: Report by the Spanish Foundation for the Brain.
    García-Ramos R; López Valdés E; Ballesteros L; Jesús S; Mir P
    Neurologia; 2016; 31(6):401-13. PubMed ID: 23816428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Report by the Spanish Foundation for the Brain on the social impact of amyotrophic lateral sclerosis and other neuromuscular disorders.
    Camacho A; Esteban J; Paradas C
    Neurologia (Engl Ed); 2018; 33(1):35-46. PubMed ID: 25825074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The prevalence and pharmacological cost of Parkinson's disease in Spain].
    Abasolo-Osinaga E; Abecia-Inchaurregui LC; Fernández-Díaz E; Barcenilla-Laguna A; Bañares-Onraita T
    Rev Neurol; 2006 Dec 1-15; 43(11):641-5. PubMed ID: 17133323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Burden of disease related to Parkinson's disease in Spain in the year 2000.
    Cubo E; Alvarez E; Morant C; de Pedro Cuesta J; Martínez Martín P; Génova R; Freire JM
    Mov Disord; 2005 Nov; 20(11):1481-7. PubMed ID: 16037922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Epidemiology of Parkinson's disease in Spain and its contextualisation in the world].
    Benito-Leon J
    Rev Neurol; 2018 Feb; 66(4):125-134. PubMed ID: 29435969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parkinson's in the oldest old: Impact on estimates of future disease burden.
    Myall DJ; Pitcher TL; Pearson JF; Dalrymple-Alford JC; Anderson TJ; MacAskill MR
    Parkinsonism Relat Disord; 2017 Sep; 42():78-84. PubMed ID: 28693940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The economic impact of Parkinson's disease.
    Findley LJ
    Parkinsonism Relat Disord; 2007 Sep; 13 Suppl():S8-S12. PubMed ID: 17702630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Report by the Spanish Foundation of the Brain on the social impact of Alzheimer disease and other types of dementia.
    Villarejo Galende A; Eimil Ortiz M; Llamas Velasco S; Llanero Luque M; López de Silanes de Miguel C; Prieto Jurczynska C
    Neurologia (Engl Ed); 2021; 36(1):39-49. PubMed ID: 29249303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibromyalgia: Prevalence, epidemiologic profiles and economic costs.
    Cabo-Meseguer A; Cerdá-Olmedo G; Trillo-Mata JL
    Med Clin (Barc); 2017 Nov; 149(10):441-448. PubMed ID: 28734619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic and health-related quality of life considerations of new therapies in Parkinson's disease.
    Rubenstein LM; DeLeo A; Chrischilles EA
    Pharmacoeconomics; 2001; 19(7):729-52. PubMed ID: 11548910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mortality from Parkinson's disease in Spain (1980-1985). Distribution by age, sex and geographic areas].
    Burguera JA; Catalá J; Taberner P; Muñoz R
    Neurologia; 1992 Mar; 7(3):89-93. PubMed ID: 1571189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A report on the WHO working group on Parkinson's disease.
    Janca A
    Neuroepidemiology; 1999; 18(5):236-40. PubMed ID: 10461048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the clinical profile of Parkinson's disease between Spanish and Cameroonian cohorts.
    Cubo E; Doumbe J; Martinez-Martin P; Rodriguez-Blazquez C; Kuate C; Mariscal N; Lopez I; Noubissi G; Mapoure YN; Jon JL; Mbahe S; Tchaleu B; Catalan MJ;
    J Neurol Sci; 2014 Jan; 336(1-2):122-6. PubMed ID: 24183853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with the quality of life of subjects with Parkinson's disease and burden on their caregivers.
    Rodríguez-Violante M; Camacho-Ordoñez A; Cervantes-Arriaga A; González-Latapí P; Velázquez-Osuna S
    Neurologia; 2015 Jun; 30(5):257-63. PubMed ID: 24704248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of Parkinson's disease and other types of Parkinsonism. A door-to-door survey in Bidasoa, Spain.
    Bergareche A; De La Puente E; López de Munain A; Sarasqueta C; de Arce A; Poza JJ; Martí-Massó JF
    J Neurol; 2004 Mar; 251(3):340-5. PubMed ID: 15015016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Epidemiology of parkinsonism in the Guadalajara Health Area].
    Martínez-Pérez JA; Ortiz-García R; González-Zerega A; López-Gosling I; Guzmán A; Dragomir E
    Semergen; 2014 Sep; 40(6):305-12. PubMed ID: 24556169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
    Maurel F; Lilliu H; Le Pen C
    Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating the direct and indirect costs associated with Parkinson's disease.
    Rodríguez-Blázquez C; Forjaz MJ; Lizán L; Paz S; Martínez-Martín P
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):889-911. PubMed ID: 26511768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alzheimer's and Parkinson's Diseases: Expected Economic Impact on Europe-A Call for a Uniform European Strategy.
    Maresova P; Klimova B; Novotny M; Kuca K
    J Alzheimers Dis; 2016 Oct; 54(3):1123-1133. PubMed ID: 27567862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measuring the burden and mortality of hospitalisation in Parkinson's disease: A cross-sectional analysis of the English Hospital Episodes Statistics database 2009-2013.
    Low V; Ben-Shlomo Y; Coward E; Fletcher S; Walker R; Clarke CE
    Parkinsonism Relat Disord; 2015 May; 21(5):449-54. PubMed ID: 25737205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.